OBJECTIVE: Pentraxin 3 (PTX3), a key component of innate immunity, is a strong marker of disease severity in coronary artery disease (CAD). The aim of this study was to compare levels of serum PTX3 in CAD patients with and without inflammatory rheumatic disease (IRD) and in healthy controls. METHODS: We examined 69 patients with IRD (CAD/IRD group) and 53 patients without IRD (CAD/non-IRD) referred to coronary artery bypass grafting, and 30 healthy controls. RESULTS: The mean +/- SD serum PTX3 level in the CAD/IRD group was 1.96 +/- 0.98 ng/ml; this was statistically significantly higher than that of the CAD/non-IRD (1.41 +/- 0.74 ng/ml) and healthy control (1.21 +/- 0.59 ng/ml) groups. In contrast to most other IRDs, serum PTX3 levels were relatively low in patients with systemic lupus erythematosus (SLE) and other systemic connective tissue diseases. In sex- and age-adjusted analysis, IRD, acute coronary syndromes, and low alcohol intake were associated with higher serum PTX3 levels. CONCLUSION: CAD patients with IRD had higher mean serum PTX3 levels than patients without IRD and healthy controls. In addition, acute coronary syndromes and low alcohol intake independently predicted higher serum PTX3 levels. Higher serum PTX3 levels in IRD may be related to the higher cardiovascular risk of IRD patients. Circulating PTX3 could likely be used as a biomarker for severity of cardiovascular disease in IRDs; its importance, however, might be limited in SLE and related disorders.
OBJECTIVE:Pentraxin 3 (PTX3), a key component of innate immunity, is a strong marker of disease severity in coronary artery disease (CAD). The aim of this study was to compare levels of serum PTX3 in CADpatients with and without inflammatory rheumatic disease (IRD) and in healthy controls. METHODS: We examined 69 patients with IRD (CAD/IRD group) and 53 patients without IRD (CAD/non-IRD) referred to coronary artery bypass grafting, and 30 healthy controls. RESULTS: The mean +/- SD serum PTX3 level in the CAD/IRD group was 1.96 +/- 0.98 ng/ml; this was statistically significantly higher than that of the CAD/non-IRD (1.41 +/- 0.74 ng/ml) and healthy control (1.21 +/- 0.59 ng/ml) groups. In contrast to most other IRDs, serum PTX3 levels were relatively low in patients with systemic lupus erythematosus (SLE) and other systemic connective tissue diseases. In sex- and age-adjusted analysis, IRD, acute coronary syndromes, and low alcohol intake were associated with higher serum PTX3 levels. CONCLUSION:CADpatients with IRD had higher mean serum PTX3 levels than patients without IRD and healthy controls. In addition, acute coronary syndromes and low alcohol intake independently predicted higher serum PTX3 levels. Higher serum PTX3 levels in IRD may be related to the higher cardiovascular risk of IRD patients. Circulating PTX3 could likely be used as a biomarker for severity of cardiovascular disease in IRDs; its importance, however, might be limited in SLE and related disorders.
Authors: Ana Paula Moreira; Karen A Cavassani; Ugur B Ismailoglu; Rikki Hullinger; Michael P Dunleavy; Darryl A Knight; Steven L Kunkel; Satoshi Uematsu; Shizuo Akira; Cory M Hogaboam Journal: J Clin Invest Date: 2011-10-17 Impact factor: 14.808
Authors: L Wirestam; H Enocsson; T Skogh; M L Eloranta; L Rönnblom; C Sjöwall; J Wetterö Journal: Clin Exp Immunol Date: 2017-03-31 Impact factor: 4.330
Authors: J Jylhävä; A Haarala; M Kähönen; T Lehtimäki; A Jula; L Moilanen; Y A Kesäniemi; M S Nieminen; M Hurme Journal: Clin Exp Immunol Date: 2011-03-10 Impact factor: 4.330
Authors: Jeremiah R Brown; Jeffrey P Jacobs; Shama S Alam; Heather Thiessen-Philbrook; Allen Everett; Donald S Likosky; Kevin Lobdell; Moritz C Wyler von Ballmoos; Devin M Parker; Amit X Garg; Todd Mackenzie; Marshall L Jacobs; Chirag R Parikh Journal: Ann Thorac Surg Date: 2018-08-04 Impact factor: 4.330
Authors: Maciej Lech; Christoph Römmele; Onkar P Kulkarni; Heni Eka Susanti; Adriana Migliorini; Cecilia Garlanda; Alberto Mantovani; Hans-Joachim Anders Journal: PLoS One Date: 2011-05-27 Impact factor: 3.240
Authors: Suan-Sin Foo; Weiqiang Chen; Adam Taylor; Kuo-Ching Sheng; Xing Yu; Terk-Shin Teng; Patrick C Reading; Helen Blanchard; Cecilia Garlanda; Alberto Mantovani; Lisa F P Ng; Lara J Herrero; Suresh Mahalingam Journal: PLoS Pathog Date: 2015-02-19 Impact factor: 6.823